Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02669576
Other study ID # 15-6578-BO
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date May 2022

Study information

Verified date December 2022
Source Universität Duisburg-Essen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled trial aims to investigate the effectiveness of a mind body day care clinic program of breast cancer patients undergoing endocrine therapy.


Description:

Breast cancer patients undergoing endocrine therapy are often suffering from side effects. This randomized controlled trial analyzes the effects of an 11-week day care clinic group program including mind body medical elements (yoga, relaxation, meditation, education) and acupuncture in breast cancer patients with menopausal symptoms under endocrine therapy.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date May 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Histological diagnosed breast cancer (Stage I-III), no metastases - Current endocrine therapy (minimum 3 months) - Score of 9 or greater on the Menopausal Rating Scale (MRS) - Signed informed consent Exclusion Criteria: - Severe other somatic or psychiatric comorbidity - Pregnancy - Planned or existing chemotherapy, radiation or other cure treatment - Participation in other clinical studies with behaviour-oriented, psychological or compementary medicine intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mind body medicine day care clinic
Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
Other:
Usual care
Patients continue usual care by their practitioner

Locations

Country Name City State
Germany Evang. Kliniken Essen-Mitte Essen NRW

Sponsors (1)

Lead Sponsor Collaborator
Universität Duisburg-Essen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Mindfulness Conscious Presence and Self Control Scale (CPSC) week 11
Other Social Support Berlin Social Support Scale (BSSS) week 11
Other Expectation Visual Analogue Scale (VAS) week 0
Other Statisfaction Client Satisfaction Questionnaire (CSQ) week 11
Primary Menopausal symptoms Menopause Rating Scale (MRS) week 11
Secondary General health-related quality of life Functional Assessment of Cancer Therapy - General Questionaire (FACT-G) week 11
Secondary Spiritual health-related quality of life Functional Assessment of Cancer Therapy - Spirutual Subscale (FACT-SP) week 11
Secondary Fatigue Functional Assessment of Cancer Therapy - Fatigue Subscale (FACT-F) week 11
Secondary Mental wellbeing Hospital Anxiety and Depression Scale (HADS) week 11
Secondary Stress Perceived Stress Scale (PSS) week 11
Secondary Compliance Medication Adherence Report Scale (MARS) week 11
Secondary Adverse events Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 week 11
Secondary Menopausal smptoms Menopause Rating Scale (MRS) week 23
Secondary Genaeral health-related quality of life Functional Assessment of Cancer Therapy - General Questionaire (FACT-G) week 23
Secondary Spiritual health-related quality of life Functional Assessment of Cancer Therapy - Spirutual Subscale (FACT-SP) week 23
Secondary Fatigue Functional Assessment of Cancer Therapy - Fatigue Subscale (FACT-F) week 23
Secondary Mental wellbeing Hospital Anxiety and Depression Scale (HADS) week 23
Secondary Stress Perceived Stress Scale (PSS) week 23
Secondary Compliance Medication Adherence Report Scale (MARS) week 23
Secondary Adverse Events Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 week 23
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2